Study of avutometinib and defactinib for thyroid cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests two oral drugs (avutometinib and defactinib) for people with certain types of advanced thyroid cancer that have specific genetic changes. The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of thyroid cancer (papillary, follicular, Hurthle cell, poorly differentiated, or anaplastic) that has spread or come back and cannot be removed with surgery.
- Your tumor has a specific genetic change, such as a RAS mutation, NF1 mutation, RET rearrangement, NTRK rearrangement, ALK rearrangement, or certain BRAF alterations (not V600E/K).
- For differentiated thyroid cancer: your disease is getting worse despite treatment (e.g., new or growing tumors) within the last 14 months, and you have had radioactive iodine (RAI) therapy that is no longer working or you cannot have RAI.
- You have not taken certain cancer drugs (MEK inhibitor, FAK inhibitor, or certain BRAF inhibitors) before, unless it was a short course to enhance RAI.
- You are 18 or older, with good daily function (ECOG 0 or 1), and adequate organ function (heart, liver, kidneys, blood counts).
- You must be willing to have two research biopsies of a tumor, unless it is not safe or feasible.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, anlotinib (a targeted therapy) and benmelstobart (an immunotherapy), for people with differentiated thyroid cancer that has spread or cannot be removed. It may be an option if your cancer did not respond to or got worse after first treatment.
This trial tests two oral drugs, avutometinib and defactinib, for people with a specific type of stomach cancer called diffuse gastric cancer. The goal is to see if these drugs can help shrink or slow the cancer.
This trial tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) for people with advanced lung adenocarcinoma that has a specific gene mutation (LKB1) and has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this new combination can shrink tumors or slow cancer growth.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
This trial tests a combination of three drugs for people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if combining these drugs can shrink tumors or slow cancer growth.
This trial tests a combination of three targeted drugs (avutometinib, defactinib, and everolimus) for people whose endometrial cancer has a specific change in the RAS pathway and has not responded to other treatments. The goal is to see if this drug combo can shrink tumors or slow their growth.
Hear when a new Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.